Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease
Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.
03 July 2024
03 July 2024
Leqembi will now face a challenger as donanemab enters the market under the brand name Kisunla.
Advances in automation in T-cell production are beginning to help make life-changing therapies more accessible to a growing number of patients in oncology and beyond.
The company has announced plans to lay off 39 employees, with most of the workforce cuts expected in coming months.
The company scrapped the envafolimab trial, after an independent review found the study was unlikely to meet its primary endpoint.
Chronic migraine is traditionally treated with preventative treatment options such as front-line therapy.
The latest FDA decision removes the label restrictions imposed during the asset’s accelerated approval in the US.
Academic institutions and nonprofit organisations are jumping in to save access to complex gene therapies.
The deal also gives Eli Lilly exclusive rights to acquire Radionetics for $1bn after the exercise period is over.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.